LORAZEPAM TABLET

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

LORAZEPAM

Mevcut itibaren:

SANIS HEALTH INC

ATC kodu:

N05BA06

INN (International Adı):

LORAZEPAM

Doz:

2.0MG

Farmasötik formu:

TABLET

Kompozisyon:

LORAZEPAM 2.0MG

Uygulama yolu:

ORAL

Paketteki üniteler:

100/1000

Reçete türü:

Targeted (CDSA IV)

Terapötik alanı:

BENZODIAZEPINES

Ürün özeti:

Active ingredient group (AIG) number: 0110731002; AHFS:

Yetkilendirme durumu:

CANCELLED POST MARKET

Yetkilendirme tarihi:

2021-12-13

Ürün özellikleri

1
PRESCRIBING INFORMATION
LORAZEPAM
LORAZEPAM TABLeTS
MANUFACTURER’S STANDARD
0.5 mg, 1 mg, 2 mg
ANXIOLYTIC-SEDATIVE
SANIS HEALTH INC.
1 President’s Choice Circle,
Brampton, Ontario
L6Y 5S5
www.sanis.com DATE OF REVISION:
January 7, 2020
Control No.: 234684
2
TABLE OF CONTENTS
ACTION
.............................................................................................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................................
4
CONTRAINDICATIONS
..................................................................................................................
4
WARNINGS
.......................................................................................................................................
4
PRECAUTIONS
.................................................................................................................................
7
DRUG INTERACTIONS
...................................................................................................................
8
ADVERSE REACTIONS
................................................................................................................
10
SYMPTOMS AND TREATMENT OF OVERDOSAGE
............................................................... 11
DOSAGE AND ADMINISTRATION
.............................................................................................
12
AVAILABILITY OF DOSAGE FORMS
........................................................................................
13
PHARMACOLOGY
........................................................................................................................
14
TOXICOLOGY
................................................................................................................................
18
REFERENCES
.................................................................................................................................
22
PART III: CONSUMER INFO